Immuneering
IMRX· Manufacturing· Fiscal year ends in December
CEO pay in FY2022Stock -70.0% in FY2022
Benjamin J. Zeskind, Ph.D. is the CEO of Immuneering and was paid $2.1M in FY2022 (Dec).
Pay$100 in the stock at the end of FY21 → $30
Executives3
See all- 1Benjamin J. Zeskind, Ph.D.President and Chief Executive OfficerFY2022
- 2Brett Hall, Ph.D.Chief Scientific OfficerFY2022
- 3Michael D. BookmanChief Legal OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allImmuneering paid its one named executive on file $890.4K in FY2025 (Dec).
| Name | ||
|---|---|---|
| Michael D. BookmanChief Legal Officer | Not disclosed | |
| Benjamin J. Zeskind, Ph.D.President and Chief Executive Officer | Not disclosed | |
| Brett Hall, Ph.D.Chief Scientific Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Immuneering. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board3
See all- Robert J. CarpenterDirector · 16 yr on the boardIndependentCompensation—Paid as an executive
- Peter FeinbergDirector · 4 yr on the boardIndependentAudit, Compensation (Chair), Nominating and Corporate Governance—Paid as an executive
- Diana F. Hausman, M.D.Director · 3 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
No new filings about this company in the feed.
Filings6
See all| Proxy statement | DEF 14A | Apr 20, 2026 | FY2025 |
| Annual report | 10-K | Mar 6, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Mar 20, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 23, 2024 | FY2023 |
| Annual report | 10-K | Mar 1, 2024 | FY2023 |
